Growth factor alterations in advanced diabetic retinopathy: A possible role of blood retina barrier breakdown

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Pfeiffer, Andreas ^a   Spranger, Joachim ^a   Meyer Schwickerath, Rolf ^b   Schatz, Helmut ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

BLOOD RETINA BARRIER; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC RETINOPATHY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IRIS RUBEOSIS; PRIORITY JOURNAL; RETINA ISCHEMIA; VITREOUS BODY;

EID: 0030963671     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s26     Document Type: Conference Paper

References (37)

1. Greene DA, Lattimer SA, Sima AA: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316:599-606, 1987
2. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
3. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van-den-Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
4. Dunlop ME, Larkins RG: Pancreatic islets synthesize phospholipids de novo from glucose via acyl-dihydroxyacetone phosphate. Biochern Biophys Res Commun 132:467-473, 1985
5. DeRubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes. Diabetes 43:1-8, 1994
6. Ishizuka T, Hoffman J, Cooper DR, Watson JE, Pushkin DB, Farese RV: Glucose-induced synthesis of diacylglycerol de novo is associated with translocation (activation) of protein kinase C in rat adipocytes. FEBS Lett 249:234-238, 1989
7. Kirstein M, Aston C, Hintz R, Vlassara H: Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 90:439-446, 1992
8. Patz A: Clinical and experimental studies on retinal neovascularization. Am J Ophthalmol 94:715-743, 1982
9. Tesfaye S, Malik R, Ward JD: Vascular factors in diabetic neuropathy. Diabetologia 37:847-854, 1994
10. Border WA, Ruoslahti E: Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 90:1-7, 1992
11. McClain DA, Paterson AJ, Roos MD, Wei X, Kudlow JE: Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 89:8150-8154, 1992
12. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA: Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care 17:818-823, 1994
13. Pfeiffer A, Schatz H: Diabetic microvascular complications and growth factors. Exp Clin Endocrinol 103:7-14, 1995
14. Harrison AA, Dunbar PR, Neale TJ: Immunoassay of platelet-derived growth factor in the blood of patients with diabetes mellitus. Diabetologia 37:1142-1146, 1994
15. Bertello P, Veglio F, Pinna G, Gurioli L, Molino P, Alban S, Chandussi L: Plasma endothelin in NIDDM patients with and without complications. Diabetes Care 17:574-576, 1994
16. Shimizu K, Kobayashi Y, Muraoka K: Midperipheral fundus involvement in diabetic retinopathy. Ophthalmology 88:601-609, 1981
17. Merimee TJ: Diabetic retinopathy. N Engl J Med 322:978-982, 1990
18. Hyer SL, Sharp PS, Burrin ,JM, Kohner EM: Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF-I) during continuous subcutaneous insulin infusion. Horm Metab Res 21:18-22, 1989
19. Sharp PS, Fallon TJ, Brazier OJ, Sandier L, Joplin GF, Kohner EM: Long term follow up of patients who underwent yttrium-90 pituitary implantation for treatment of diabetic retinopathy. Diabetologia 30:199-207, 1987
20. Grant M, Russel B, Fitzgerald C, Merimee TJ: Insulin-like growth factors in the vitreous. Diabetes 35:416-420, 1986
21. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H: Vitreous levels of the insulin-like growth factor I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. J Clin Invest 92:2620-2635, 1993
22. Grant MB, Marnes RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J: Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 36:282-291, 1993
23. Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337-4345, 1986
24. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544-4548, 1989
25. Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB: Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience 44:613-625, 1991
26. McAvoy JW, Chamberlain CG: Growth factors in the eye. Prog Growth Factor Res 2:29-43, 1990
27. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Klein M, Schatz H: Vitreous levels of TGFβ-subtypes: decrease in neovascular eye disease and diabetic retinopathy (Abstract). Diabetologia 37 (Suppl. 1):A36, 1995
28. Roberts AB, Sporn MB: Peptide growth factors and their receptors I. In Handbook of Experimental Pharmacology. 1990 ed. Sporn MB, Roberts AB, Eds. Berlin, Springer, 1990, p. 419-472
29. Miyazano K, Heldin CH: Latent forms of TGF-β: molecular structure and mechanisms of activation. In Clinical Applications of TGF-β. Ciba Foundation Symposium Vol. 157. Sporn MB, Ed. Chichester, U.K., Wiley, 1991, p. 81-92
30. Lucas C, Fendly BM, Mukku VR, Wong WL, Palladino MA: Generation of antibodies and assays of transforming growth factor beta. Methods Enzymol 198:303-318, 1991
31. Connor TB, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM: Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 83:1661-1666, 1989
32. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H: Elevated plasma levels of transforming growth factor-β1 in non-insulin-dependent diabetes mellitus. Diabetes Care 19:1113-1117, 1996
33. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581, 1995
34. Kim SJ, Park K, Rudkin BB, Dey BR, Sporn MB, Roberts AB: Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC 12 cells. J Biol Chem 269:3739-3744, 1994
35. Hanneken A, de-Juan E Jr, Lutty GA, Fox GM, Schiffer S, Hjelmeland LM: Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthatmol 109:1005-1011, 1991
36. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A: TNF-α-Spiegel im Glaskörper: Anstieg bei neovaskulären Augenkrankheiten und proliferativer diabetischer Retinopathie. Med Klin 90:134-137, 1995
37. Hammes Hans-P, Brownlee M, Jonczyk A, Sutter A, Preissner KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 2:529-533, 1996